Compare CUE & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | GAUZ |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 22.5M |
| IPO Year | 2017 | 2019 |
| Metric | CUE | GAUZ |
|---|---|---|
| Price | $0.26 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 762.9K | 226.7K |
| Earning Date | 03-16-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | $22.59 |
| Revenue Next Year | $25.00 | $59.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.23 | $0.48 |
| 52 Week High | $1.05 | $10.76 |
| Indicator | CUE | GAUZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 56.72 |
| Support Level | $0.23 | $0.48 |
| Resistance Level | $0.35 | $1.59 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 18.42 | 48.51 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.